NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF)

This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary exacerbations of CF in oral form and is anticipated to begin phase 1 development in 2022 in inhaled form for maintenance of ventilatory function in stable CF patients (chronic, continuous use). NovaBiotics continues to explore the potential of NM001 in other inflammatory-infectious respiratory disease & against non-respiratory pathogens.

The full article published in Frontiers in Cellular and Infection Microbiology as part of the Research Topic ‘Pseudomonas aeruginosa Pathogenisis: Virulence, Antibiotic Tolerance and Resistance, Stress Responses and Host-pathogen Interactions’ can be accessed here Frontiers NM001 Article